Thinly traded HOOKIPA Pharma (HOOK +2.1%) is up, albeit on a scant 38K shares, on the heels of its announcement that collaboration partner Gilead Sciences (GILD -0.2%) will advance its HBV and HIV vectors toward development, a decision that triggers another milestone payment under the HBV program.
Gilead has agreed to reserve manufacturing capacity for the vectors and has expanded the resources allocated to the partnership inked in June 2018.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.